CN101676266B - Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same - Google Patents
Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same Download PDFInfo
- Publication number
- CN101676266B CN101676266B CN2008102001060A CN200810200106A CN101676266B CN 101676266 B CN101676266 B CN 101676266B CN 2008102001060 A CN2008102001060 A CN 2008102001060A CN 200810200106 A CN200810200106 A CN 200810200106A CN 101676266 B CN101676266 B CN 101676266B
- Authority
- CN
- China
- Prior art keywords
- deuterium
- phenyl
- compound
- chloro
- urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1nccc(Cl)c1 Chemical compound *c1nccc(Cl)c1 0.000 description 5
- ASPDJZINBYYZRU-UHFFFAOYSA-N Nc(cc1)cc(C(F)(F)F)c1Cl Chemical compound Nc(cc1)cc(C(F)(F)F)c1Cl ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N Nc(cc1)ccc1O Chemical compound Nc(cc1)ccc1O PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- FYBNFLRGZHGUDY-UHFFFAOYSA-N O=C(c1nccc(Cl)c1)Cl Chemical compound O=C(c1nccc(Cl)c1)Cl FYBNFLRGZHGUDY-UHFFFAOYSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N OC(c1ncccc1)=O Chemical compound OC(c1ncccc1)=O SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a deuterium-substituted omega-diphenylurea and its derivatives, as well as their pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition containing a pharmaceutically acceptable carrier and the deuterium-substituted omega-diphenylurea and its derivatives as well as their pharmaceutically acceptable salts. The deuterium-substituted diphenylurea of the invention can be used for treating and preventing the cancer and related diseases.
Description
Technical field
The present invention relates to the ω-diphenyl urea and the derivative in deuterium generation and the pharmaceutical composition that contains this compound.
Background technology
Known ω-diphenyl urea derivatives is the compound of c-RAF kinase activity.The diphenyl urea that one class ω-carboxyl aryl replaces is for example disclosed in WO2000/042012, and the purposes in treatment cancer and relative disease.
ω-diphenyl urea compound such as Xarelto (Sorafenib) are found to be the kinase whose inhibitor of c-RAF at first, discover constantly that afterwards it can also suppress activity (the Curr Pharm Des 2002 of the Tyrosylprotein kinase of vascular endothelial growth factor-2 (VEGFR-2), vascular endothelial growth factor-3 (VEGFR-3) and platelet derived growth factor-β (PDGFR-β); 8:2255-2257), so it is referred to as many kinase inhibitor, has dual antitumor action.
Xarelto (Sorafenib), trade(brand)name Nexavar, be a kind of novel oral many kinase inhibitor by the common development of Beyer Co., Ltd and ONXY company, since it at one at the excellent performance in the III phase clinical study of kidney in late period, fast ratified to be used for the treatment of late period renal cell carcinoma by FDA in December, 2005, and go on the market in China in November, 2006.
Yet this area still needs to develop has the compound that suppresses active or better pharmacodynamics performance to the raf kinases.
Summary of the invention
Purpose of the present invention just provides novel compound with raf kinase inhibiting activity and better pharmacodynamics performance of a class and uses thereof.
In a first aspect of the present invention, provide ω-diphenyl urea compound or its crystal formation, pharmacy acceptable salt, hydrate or the solvate in the deuterium generation shown in a kind of formula (I):
In the formula:
R
1Be halogen (as F, Cl, or Br), the C1-C4 alkyl in deuterium one or many deuterium generation or full generation;
R
2Be deuterium generation, one or many deuterium generation or the full deuterium C1-C4 alkyl in generation, the perhaps part or all of C1-C4 alkyl that replaces of halogen;
R
3Be hydrogen, deuterium or halogen (as F, Cl, or Br);
R
4Be hydrogen, deuterium, or halogen (as F, Cl, or Br);
R
5Be hydrogen, deuterium or halogen (as F, Cl, or Br);
R
6It is C1-C4 alkyl hydrogen, deuterium or one or many deuterium generation or full deuterium generation;
R
7It is C1-C4 alkyl hydrogen, deuterium or one or many deuterium generation or full deuterium generation;
Supplementary condition are R
2, R
3, R
4, R
5, R
6Or R
7In at least one be deuterium generation or deuterium.
In another preference, deuterium is greater than natural deuterium isotopic content (0.015%) in the deuterium isotopic content of deuterium the position of substitution at least, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, more preferably greater than 99%.
In another preference, formula (I) compound contains 1 D atom at least, more preferably 3 D atoms, more preferably 5 D atoms.
In another preference, R
6Or R
7Be independently selected from respectively: the ethyl in the methyl in deuterium generation or deuterium generation; More preferably, be selected from a deuterium methyl, two deuterium methyl, three deuterium methyl, a deuterium ethyl, two deuterium ethyls, three deuterium ethyls, four deuterium ethyls or five deuterium ethyls.
In another preference, one or more R
4It is deuterium.
In another preference, one or more R
5It is deuterium.
In another preference, described compound is the preferred compound that is selected from down group:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 '-two deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 '-deuterium methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2-deuterium-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2,6-two deuteriums-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methyl-N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N, N-two (1 ', 1 ', 1 '-three deuterium methyl) formamyl)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2,6-two deuteriums-4-(2-(N-1 ', 1 ', 1 ' three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-deuterium-6-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals) 4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 '-two deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 2 ', 2 ', 2 '-five deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea;
Or N-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea.
In a second aspect of the present invention, a kind of method of pharmaceutical compositions is provided, comprise step: with the compound described in pharmaceutically acceptable carrier and the first aspect present invention, or its crystal formation, pharmacy acceptable salt, hydrate or solvate mix, thereby form pharmaceutical composition.
In a third aspect of the present invention, a kind of pharmaceutical composition is provided, it is characterized in that it contains the compound described in pharmaceutically acceptable carrier and the first aspect present invention, or its crystal formation, pharmacy acceptable salt, hydrate or solvate.
In another preference, described pharmaceutical composition is injection, wafer, tablet, pill, powder or granule.
In another preference, described pharmaceutical composition also contains other medicine, and described other medicine is the medicine of cancer, cardiovascular disorder, inflammation, immunological disease, ephrosis, blood vessel generation (angiogenesis), prostatosis.
More preferably, described medicine comprises (but being not limited to): 5 FU 5 fluorouracil, AV412, Avastin TM (avastin, bevacizumab), bexarotene (bexarotene), Velcade (bortezomib), calcitriol (calcitriol), how card is for Buddhist nun (canertinib), capecitabine (capecitabine), carbon platinum (carboplatin), celecoxib (celecoxib), Cetuximab (cetuximab), CHR-2797, cis-platinum (cisplatin), Dasatinib (dasatinib), digoxin (digoxin), enzastaurin, erlotinib (Erlotinib), etoposide (etoposide), everolimus (everolimus), fulvestrant (fulvestrant), Gefitinib (gefitinib), 2,2-difluoro deoxycytidine (gemcitabine), Sophoricol (genistein), imatinib (imatinib), Rinotecan (irinotecan), lapatinibditosylate (lapatinib), Revlimid (lenalidomide), letrozole (letrozole), folinic acid (leucovorin), horse trastuzumab (matuzumab), oxaliplatin (oxaliplatin), taxol (paclitaxel), handkerchief Buddhist nun monoclonal antibody (panitumumab), the granulocyte colony-stimulating factor of PEGization (pegfilgrastin), the alpha-interferon of PEGization (peglated alfa-interferon), pemetrexed (pemetrexed);
E, husky platinum (satraplatin), sirolimus (sirolimus), Xarelto (sorafenib), Sutent (sutent, sunitinib), sulindac (sulindac), taxotere (taxotere), Temozolomide (temodar, temozomolomide), Torisel (temsirolimus), TG01, tipifarnib, trastuzumab (trastuzumab), valproic acid (valproic acid), Vinflunine (vinflunine), Volociximab, vorinostat and XL647.
In a fourth aspect of the present invention, the compound described in the first aspect present invention is provided, or the purposes of its crystal formation, pharmacy acceptable salt, hydrate or solvate, they are used to the pharmaceutical composition that preparation suppresses phosphokinase (as the raf kinases).
In another preference, described pharmaceutical composition is used for the treatment of and prevents following disease: (angiogenesis) or prostatosis take place in cancer, cardiovascular disorder, inflammation, immunological disease, ephrosis, blood vessel.
In another preference, described cancer comprises (but being not limited to): non-minicell lung cancer, uterus carcinoma, the rectum cancer, the cancer of the brain, a cancer, neck cancer, bladder cancer, prostate cancer, mammary cancer, solid tumor, kidney, leukemia, liver cancer, cancer of the stomach or carcinoma of the pancreas.
In a fifth aspect of the present invention, a kind of methods of treatment is provided, it comprises step: use the compound described in the first aspect present invention for the object of needs treatment, or its crystal formation, pharmacy acceptable salt, hydrate or solvate, or use the pharmaceutical composition described in the third aspect present invention, thereby suppress phosphokinase (as the raf kinases).
Description of drawings
Fig. 1 is serum drug level (ng/ml) graphic representation behind the oral 3mg/kg control compound of the male SD rat CM4306.
Fig. 2 is serum drug level (ng/ml) graphic representation behind the oral 3mg/kg The compounds of this invention of the male SD rat CM4307.
Embodiment
The inventor is through research, be surprised to find that, ω-the diphenyl urea in deuterium of the present invention generation and pharmacy acceptable salt thereof are compared with the compound without deuterium generation, have obviously more excellent pharmacokinetics and/or pharmacodynamics performance, therefore be more suitable for kinase whose compound as inhibition raf, and then the medicine of more suitable preparation treatment cancer and relative disease.Finished the present invention on this basis.
With deuterium for compound N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 '; 1 '; 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (Compound C M4307) and not N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methylamino the formyl radical)-4-pyridyl oxygen) phenyl) urea (Compound C M4306) in deuterium generation be example
The pharmacokinetics experimental result shows that CM4307 is than the transformation period T of CM4306
1/2Prolong area under curve AUC
0-∞CM4307 is than the remarkable increase of CM4306, and CM4307 reduces than the apparent clearance rate of CM4306.
Definition
As used herein, " halogen " refers to F, Cl, Br and I.More preferably, halogen atom is selected from F, Cl and Br.
As used herein, " alkyl " comprises the alkyl of straight or branched.Preferred alkyl is the C1-C4 alkyl, for example methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl etc.
As used herein, " deuterium generation " refers to that the one or more hydrogen in compound or the group are replaced by deuterium.Deuterium is for being a replacement, two replacements, polysubstituted or full replacement.
In another preference, deuterium is greater than natural deuterium isotopic content (0.015%), more preferably greater than 50% in the deuterium isotopic content of deuterium the position of substitution, more preferably greater than 75%, more preferably greater than 95%, more preferably greater than 97%, more preferably greater than 99%, more preferably greater than 99.5%.
In another preference, formula (I) compound contains 1 D atom at least, more preferably 3 D atoms, more preferably 5 D atoms.
Activeconstituents
As used herein, term " The compounds of this invention " refers to the compound shown in the formula (I).This term also comprises and various crystalline forms, pharmacy acceptable salt, hydrate or the solvate of formula (I) compound.
As used herein, term " pharmacy acceptable salt " refers to the formed salt that is suitable as medicine of The compounds of this invention and acid or alkali.Pharmacy acceptable salt comprises inorganic salt and organic salt.The preferred salt of one class is The compounds of this invention and the sour salt that forms.Being fit to the salifiable acid of shape includes, but are not limited to: mineral acids such as hydrochloric acid, Hydrogen bromide, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetate, propionic acid, oxalic acid, propanedioic acid, succsinic acid, fumaric acid, toxilic acid, lactic acid, oxysuccinic acid, tartrate, citric acid, picric acid, methylsulfonic acid, benzene methanesulfonic acid, organic acids such as Phenylsulfonic acid; And acidic amino acid such as aspartic acid, L-glutamic acid.
The preparation method
More specifically describe the preparation method of formula of the present invention (I) structural compounds below, but these concrete grammars do not constitute any restriction to the present invention.The compounds of this invention can also be chosen various synthetic methods that will describe in this manual or known in the art wantonly and combine and make easily, and such combination can be easy to carry out by those skilled in the art in the invention.
The preparation method of the ω-diphenyl urea in the present invention uses not deuterium generation and the salt of physical compatibility thereof is known.The preparation of the ω-diphenyl urea in corresponding deuterium generation can be a raw material for initial compounds with corresponding deuterium, synthesizes with same route.For example, formula of the present invention (I) compound can be by the preparation method described in the WO 2000/042012 preparation, and difference is to be used for deuterium generation in reaction raw material replaces the non-deuterium raw material in generation.
Usually, in preparation flow, each reaction in inert solvent, is carried out to reflux temperature (as 0 ℃～80 ℃, preferred 0 ℃～50 ℃) in room temperature usually.Reaction times was generally 0.1 hour-60 hours, preferably was 0.5-48 hour.
With Compound C M4307 is example, and a kind of particularly preferred preparation flow is as follows:
In deuterium generation, can introduce for methylamine by deuterium.Deuterium also can be by the following method preparation of known literature method, as the hydrogenation hydrogenation reaction of deuterium for Nitromethane 99Min. for methylamine.
In the formula, r.t. represents room temperature.
Key intermediate 3 also can be synthetic from deuterated methanol by the following method.
Its concrete synthetic method has detailed explanation in embodiment 1.
Pharmaceutical composition and application process
Because The compounds of this invention has excellent in phosphokinase (Kinase) kinase whose the inhibitions activity of raf for example, so The compounds of this invention and various crystal formation thereof, pharmaceutically acceptable inorganic or organic salt, hydrate or solvate, and to contain The compounds of this invention be that the pharmaceutical composition of main active ingredient can be used for treatment, prevention and alleviates by to phosphokinase (Kinase) the kinase mediated disease of raf for example.According to prior art, The compounds of this invention can be used for treating following disease: cancer, cardiovascular disorder, obesity, diabetes or the like.
Pharmaceutical composition of the present invention comprises on The compounds of this invention in the safe and effective weight range or its pharmacology acceptable vehicle or carrier on the acceptable salt and pharmacology.Wherein " safe and effective amount " refers to: the amount of compound is enough to obviously improve the state of an illness, and is unlikely to produce severe side effect.Usually, pharmaceutical composition contains 1-2000mg The compounds of this invention/agent, more preferably, contains 10-200mg The compounds of this invention/agent.Preferably, described " potion " is a capsule or tablet.
" pharmaceutically acceptable carrier " refers to: one or more consistency solids or liquid filler or gelatinous mass, they are suitable for the people uses, and enough purity and enough low toxicity must be arranged." consistency " referred to herein as each component energy and compound of the present invention and blending mutually between them in the composition, and the drug effect of not obvious reduction compound.Pharmaceutically acceptable carrier part example has Mierocrystalline cellulose and derivative (as Xylo-Mucine, ethyl cellulose sodium, cellulose ethanoate etc.) thereof, gelatin, talcum, solid lubricant (as stearic acid, Magnesium Stearate), calcium sulfate, vegetables oil (as soya-bean oil, sesame oil, peanut oil, olive wet goods), polyvalent alcohol (as propylene glycol, glycerine, N.F,USP MANNITOL, sorbyl alcohol etc.), emulsifying agent (as to tell
), wetting agent (as sodium lauryl sulphate), tinting material, seasonings, stablizer, antioxidant, sanitas, apirogen water etc.
The method of application of The compounds of this invention or pharmaceutical composition is not particularly limited, and representational method of application comprises (but being not limited to): in oral, the knurl, rectum, parenteral (intravenously, intramuscular or subcutaneous) and topical.
The solid dosage that is used for oral administration comprises capsule, tablet, pill, powder and granule.In these solid dosages, active compound mixes with at least a conventional inert excipient (or carrier), as Trisodium Citrate or Lin Suanergai, or mixes with following compositions: (a) filler or expanding material, for example, starch, lactose, sucrose, glucose, N.F,USP MANNITOL and silicic acid; (b) tackiness agent, for example, Walocel MT 20.000PV, alginate, gelatin, Polyvinylpyrolidone (PVP), sucrose and gum arabic; (c) wetting Agent for Printing Inks, for example, glycerine; (d) disintegrating agent, for example, agar, lime carbonate, yam starch or tapioca (flour), alginic acid, some composition silicate and yellow soda ash; (e) retarding solvent, for example paraffin; (f) absorb accelerator, for example, quaternary ammonium compound; (g) wetting agent, for example hexadecanol and glyceryl monostearate; (h) sorbent material, for example, kaolin; (i) lubricant, for example, talcum, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate, or its mixture.In capsule, tablet and the pill, formulation also can comprise buffer reagent.
Solid dosage such as tablet, sugar-pill, capsule, pill and granule can adopt dressing and the preparation of shell material, as casing and other material well known in the art.They can comprise opacifying agent, and, discharge in the mode that the release of active compound or compound can postpone in this composition certain part in digestive tube.The example of adoptable embedding component is polymeric material and Wax.In case of necessity, active compound also can with above-mentioned vehicle in one or more form microencapsulation form.
The liquid dosage form that is used for oral administration comprises pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture.Except the active ingredient beyond the region of objective existence, liquid dosage form can comprise the conventional inert diluent that adopts in this area, as water or other solvent, solubilizing agent and emulsifying agent, example is known, the mixture of ethanol, Virahol, ethyl-carbonate, ethyl acetate, propylene glycol, 1,3 butylene glycol, dimethyl formamide and oil, particularly Oleum Gossypii semen, peanut oil, maize germ, sweet oil, Viscotrol C and sesame oil or these materials etc.
Except these inert diluents, composition also can comprise auxiliary agent, as wetting agent, emulsifying agent and suspension agent, sweeting agent, the agent of tender flavor and spices.
Except the active ingredient beyond the region of objective existence, suspension can comprise suspension agent, for example, and the mixture of ethoxylation isooctadecane alcohol, polyoxyethylene sorbitol and Isosorbide Dinitrate, Microcrystalline Cellulose, aluminum methylate and agar or these materials etc.
The composition that is used for parenteral injection can comprise physiologically acceptable aseptic moisture or anhydrous solution, dispersion liquid, suspension or emulsion and be used for being dissolved into again the aseptic Injectable solution or the sterilized powder of dispersion liquid.Suitable moisture and nonaqueous carrier, thinner, solvent or vehicle comprise water, ethanol, polyvalent alcohol and suitable mixture thereof.
The formulation that is used for the The compounds of this invention of topical comprises ointment, powder, patch, propellant and inhalation.Activeconstituents under aseptic condition with physiologically acceptable carrier and any sanitas, buffer reagent, or the propelling agent that may need in case of necessity is mixed together.
The compounds of this invention can be individually dosed, perhaps with other pharmaceutically acceptable compound Combined Preparation.
When making pharmaceutical composition, it is the Mammals (as the people) that the The compounds of this invention of safe and effective amount is applicable to the needs treatment, the effective dosage of dosage for pharmaceutically thinking when wherein using, for the people of 60kg body weight, day dosage is generally 1～2000mg, preferred 20～500mg.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
Compound of the present invention is compared with the compound that does not carry deuterium well known in the prior art, has series of advantages.Major advantage of the present invention comprises:
(1) The compounds of this invention to phosphokinase (Kinase) for example the raf kinases have excellent inhibition.
(2) by the metabolism in this technology change organism of deuterate, make the metabolism of medicine become difficult, this causes the reduction of first pass effect (First-pass effect).In this case, can change dosage and form prolonged action preparation, the form that it also can prolonged action preparation is improved suitability.
(3) also changed the pharmacokinetics effect by deuterate, because deuterium is completed into another hydrate film for compound, so that distribution in organism obviously is different from the compound in generation of deuterium not.
(4) with the hydrogen atom in the deuterium substitution compound, because its isotopic effect can improve compound drug level in animal body, to improve curative effect of medication.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.Unless otherwise indicated, otherwise umber and per-cent are weight part and weight percent.
Embodiment 1:N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (Compound C M4307)
Synthetic route:
Flow process 1
1, the preparation of 4-chloropyridine-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (3)
In the single neck round-bottomed flask of the 250mL that is furnished with exhaust gas processing device, add sulfur oxychloride (60mL), holding temperature is between 40～50 ℃, to wherein dripping dry DMF (2mL) slowly, after dropwising, continue to stir 10 minutes, in 20 minutes to wherein add nicotinic acid (20g in batches, 162.6mmol), the color of solution is a lilac by green transition gradually.Temperature is raised to 72 ℃, and stirring and refluxing 16 hours produces a large amount of solid sediments.Cool to room temperature with toluene (100mL) dilution, is concentrated near doing, and then uses dilution with toluene, is concentrated into dried.Filter, use toluene wash, obtain flaxen 3-chloro-pyridine-2-formyl chloride solid.With this solid joining in the tetrahydrofuran (THF) saturated solution of deuterium for methylamine slowly, holding temperature is lower than 5 ℃ under the ice bath, continues to stir 5 hours.Concentrate, add ethyl acetate, separate out white solid, filtering, filtrate is used the saturated common salt water washing, and anhydrous sodium sulfate drying is concentrated into driedly, obtains flaxen 4-chloropyridine-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (3) (20.68g), yield 73%.
1H?NMR(CDCl
3，300MHz)：8.37(d，1H)，8.13(s，1H)，7.96(br，1H)，7.37(d，1H).
2, the preparation of 4-(4-ammonia phenoxy group)-2-pyridine-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (5)
In 100mL exsiccant dry DMF, add successively p-aminophenol (9.54g, 0.087mol), potassium tert.-butoxide (10.3g, 0.092mol), solution becomes Vandyke brown, stir under the room temperature after 2 hours, to wherein add 4-chloropyridine-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) and methane amide (3) (13.68g, 0.079mol), Anhydrous potassium carbonate (6.5g, 0.0467mol), continue to stir after reacting liquid temperature is raised to 80 ℃ and spend the night.The TLC detection reaction finishes, and cool to room temperature is poured reaction solution in the mixed solution of ethyl acetate (150mL) and saturated aqueous common salt (150mL), stir layering, leave standstill the back separatory, water layer ethyl acetate extraction (100mL * 3), combining extraction liquid, with saturation water washing (100mL * 3), anhydrous sodium sulfate drying, concentrate, obtain flaxen 4-(4-ammonia phenoxy group)-2-pyridine-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (18.00g), yield 92%.
1H?NMR(CDCl
3，300MHz)：8.32(d，1H)，7.99(br，1H)，7.66(s，1H)，6.91～6.85(m，3H)，6.69(m，2H)，3.70(br，s，2H).
3, the preparation of N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea (CM4307)
In the 120mL methylene dichloride, add 5-amino-2-chloro-trifluoromethylbenzene (15.39g, 78.69mol), N, and N '-carbonyl dimidazoles (CDI) (13.55g, 83.6mmol), after the stirring at room 16 hours, to wherein dripping 4-(4-ammonia phenoxy group)-2-pyridine-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (18g slowly, methylene dichloride 73mmol) (180mL) solution continues under the room temperature to stir 18 hours.The TLC detection reaction finishes, and revolves the part methylene chloride solvent to the 100mL, and room temperature is placed a few hours, has a large amount of white solids to separate out, a large amount of washed with dichloromethane of suction filtration, solid.After filtrate concentrating removed partial solvent; separate out the part solid again; merge solid twice; wash once more with a large amount of methylene dichloride; obtain white powdered N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 '; 1 ', 1 '-three deuterium methylamino formyl radicals)-and 4-pyridyl oxygen) phenyl) the pure product of urea CM4307 (20.04g), yield 58%.
1H?NMR(CD
3OD，300MHz)：8.48(d，1H)，8.00(d，1H)，7.55(m，5H)，7.12(d，1H)，7.08(s，2H)，ESI-HRMS?m/z：C21H13D3ClF3N403，Calcd.467.11，Found?490.07(M+Na)
+.
The preparation of embodiment 2:4-chloropyridine-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (3)
A) with phthalic imidine (14.7g, 0.1mol), deuterated methanol (3.78g, 0.105mol, 1.05equiv), triphenylphosphine (28.8g, 0.11mol, 1.1equiv) be dissolved in the anhydrous tetrahydro furan, ice bath drips the tetrahydrofuran solution of DEAD (1.1equiv) down, dropwises the back stirring at room one hour.Cross post and purify, after perhaps solvent is spin-dried for, add an amount of DCM in the freezing solid after-filtration of separating out of refrigerator, filtrate is spin-dried for, and the quick again post of crossing gets pure product deuterium for methyl phthalimide 14.8g.Yield 90%.
B) deuterium is for methyl phthalimide (12.5g, 0.077mol) be dissolved in appropriate hydrochloric acid (6N, 50ml), in tube sealing backflow 24-30 hour, after reaction solution is cooled to room temperature, place refrigerator and cooled but to arrive sub-zero zero, the solid that filtration is separated out, with cold deionized water wash, collect filtrate, revolve to steam and dewater and drying obtains deuterium for methylamine hydrochloride.Add anhydrous DCM (100ml) in deuterium for methylamine hydrochloride in, and (0.5equiv), (1.5equiv), the reaction flask sealing places refrigerator reaction one day to yellow soda ash for 12.2g, 0.12mol for 6.52g, 0.038mol to add 4-chlorine apellagrin methyl ester hydrochloride.The TLC detection reaction, the after washing that finishes, drying concentrates, and crosses post and purifies.Compound 4-chloro pyridine-2-(N-1 ', 1 ', 1 '-three deuteriums are for methyl) methane amide (3), 5.67g, yield 86%.Its constitutional features is consistent with embodiment 1.
The preparation of embodiment 3 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 '-two deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: use CD
2HNH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 4 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 '-deuterium methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: use CDH
2NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 5 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace 5-amino-2-chloro-trifluoromethylbenzene, CH with 5-amino-2-chloro-three deuterium methylbenzene
3NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 6 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace nicotinic acid, CH with 2-deuterium-6-carboxyl pyridine
3NH
2Replace CD
3NH
2Thereby, make target compound.
Embodiment 7 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2-deuterium-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea;
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, 3-deuterium-4-amino-phenol is replaced p-aminophenol, CH
3NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 8 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2,6-two deuteriums-4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, and 3,5-two deuteriums-4-amino-phenol is replaced p-aminophenol, CH
3NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 9 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-deuterium-6-(N-methylamino formyl radical)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, replace 5-amino-2-chloro-trifluoromethylbenzene, CH with 5-amino-2-chloro-three deuterium methylbenzene
3NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 10 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methyl-N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: use CD
3CH
3NH replaces CD
3NH
2Thereby, make target compound.
The preparation of embodiment 11 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N, N-two (1 ', 1 ', 1 '-three deuterium methyl) formamyl)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: use CD
3CD
3NH replaces CD
3NH
2Thereby, make target compound.
The preparation of embodiment 12 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(2,6-two deuteriums-4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: use CD
2HNH
2Replace CD
3NH
2, 3,5-two deuteriums-4-amino-phenol is replaced p-aminophenol, thereby makes target compound.
The preparation of embodiment 13 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-deuterium-6-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace nicotinic acid with 2-deuterium-6-carboxyl pyridine, thereby make target compound.
The preparation of embodiment 14 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 '-two deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: CH
3CD
2NH
2Replace CD
3NH
2Thereby, make target compound.
The preparation of embodiment 15 compound Ns-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 2 ', 2 ', 2 '-five deuterium ethylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: CD
3CD
2NH
2Replace CD
3NH
2Thereby make target compound.
The preparation of embodiment 16 compound Ns-(4-chloro-3-(three deuterium methyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea:
Press the method described in the embodiment 1, difference is: replace 5-amino-2-chloro-trifluoromethylbenzene with 5-amino-2-chloro-three deuterium methylbenzene, thereby make target compound.
Embodiment 17: the pharmacokinetics evaluation in the rat
8 male Sprague-Dawley rats, in age in 7-8 week, the about 210g of body weight is divided into 2 groups, and 4 every group (rat is numbered: control group is 13-16; Experimental group is 9-12); single oral gives 3mg/kg dosage (a) to composition: not N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-methylamino the formyl radical)-4-pyridyl oxygen) phenyl) urea (control compound CM4306) in deuterium generation or (b) N-(4-chloro-3-(trifluoromethyl) the phenyl)-N ' of embodiment 1 preparation-(4-(2-(N-1 '; 1 '; 1 '-three deuterium methylamino formyl radicals)-and 4-pyridyl oxygen) phenyl) urea (The compounds of this invention CM4307), relatively its pharmacokinetic difference.
Rat adopts standard feed to raise, and gives water and zeisin.Stop to give zeisin the evening before that day of experiment, gave zeisin after the administration in 2 hours again.Test beginning fasting in preceding 16 hours.Medicine dissolves with 30%PEG400.Eye socket blood sampling, the time point of blood sampling are after the administration 0.083 hour, 0.25 hour, and 0.5 hour, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours.
Make rat suck of short duration anesthesia behind the ether, eye socket is gathered the 300uL blood sample in test tube.30ul1% heparinate solution is in vitro arranged.Before the use, test tube spends the night in 60 ℃ of oven dry.After a time point blood specimen collection is finished subsequently, put to death behind the rat etherization.
After the blood specimen collection, leniently put upside down test tube at least 5 times immediately, guarantee to be positioned on ice after the mixing fully.Blood sample separates serum centrifugal 5 minutes of 4 ℃ of 5000rpm with red corpuscle.In clean plastic centrifuge tube, show the title and the time point of compound with pipettor sucking-off 100uL serum.Serum is carrying out being kept at-80 ℃ before LC-MS analyzes.
Its result is shown in Fig. 1-2.The result shows that CM4307 is than the transformation period T of CM4306
1/2Prolong [being respectively 11.3 ± 2.1 hours and 8.6 ± 1.4 hours] area under curve AUC
0-∞CM4307 is than the remarkable increase of CM4306 [being respectively 11255 ± 2472ngh/mL and 7328 ± 336ngh/mL], and CM4307 reduces [being respectively 275 ± 52mL/h/kg and 410 ± 18.7mL/h/kg] than the apparent clearance rate of CM4306.
Find out that from top result The compounds of this invention has better medicament kinetics in animal body, thereby have better pharmacodynamics and regulation effect.
In addition, by deuterate, the metabolic process of The compounds of this invention in organism changes to some extent.Make the hydroxylation on the phenyl become difficult especially, this causes the reduction of first pass effect (First-pass effect).In this case, can change dosage and form prolonged action preparation, the form that it also can prolonged action preparation is improved suitability.
In addition, also changed the pharmacokinetics effect by deuterate, because deuterium is completed into another hydrate film for compound, so that distribution in organism obviously is different from the compound in generation of deuterium not.
Embodiment 18 pharmaceutical compositions
Compound C M4307 (embodiment 1) 20g
Starch 140g
Microcrystalline Cellulose 60g
According to a conventional method, after above-mentioned substance mixed, the common gelatine capsule of packing into obtained 1000 capsules.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Claims (5)
1. ω-diphenyl urea compound or its pharmacy acceptable salt in deuterium generation is characterized in that described compound is:
N-(4-chloro-3-(trifluoromethyl) phenyl)-N '-(4-(2-(N-1 ', 1 ', 1 '-three deuterium methylamino formyl radicals)-4-pyridyl oxygen) phenyl) urea
2. the method for a pharmaceutical compositions is characterized in that, comprises step: with pharmaceutically acceptable carrier and the described compound of claim 1, or its pharmacy acceptable salt mixes, thereby forms pharmaceutical composition.
3. a pharmaceutical composition is characterized in that, it contains pharmaceutically acceptable carrier and the described compound of claim 1, or its pharmacy acceptable salt.
4. the purposes of the described compound of claim 1 or its pharmacy acceptable salt is characterized in that, is used to prepare the pharmaceutical composition that suppresses phosphokinase.
5. purposes as claimed in claim 4 is characterized in that, described pharmaceutical composition is used for the treatment of and prevents following disease: cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102001060A CN101676266B (en) | 2008-09-19 | 2008-09-19 | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102001060A CN101676266B (en) | 2008-09-19 | 2008-09-19 | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101761325A Division CN103254126A (en) | 2008-09-19 | 2008-09-19 | Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds |
| CN201110302329.XA Division CN102516154B (en) | 2008-09-19 | 2008-09-19 | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101676266A CN101676266A (en) | 2010-03-24 |
| CN101676266B true CN101676266B (en) | 2011-10-26 |
Family
ID=42029000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102001060A Active CN101676266B (en) | 2008-09-19 | 2008-09-19 | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101676266B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103254126A (en) * | 2008-09-19 | 2013-08-21 | 苏州泽璟生物制药有限公司 | Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102803221B (en) * | 2010-03-18 | 2014-09-10 | 苏州泽璟生物制药有限公司 | Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising these compounds |
| CN102190616B (en) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production |
| US20130012548A1 (en) * | 2010-03-18 | 2013-01-10 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| JP2013536806A (en) * | 2010-09-01 | 2013-09-26 | アスセピオン ファーマスーティカル、インコーポレイテッド | Deuterated heterocyclic compounds as kinase inhibitors |
| CN109096171B (en) * | 2011-03-17 | 2022-04-01 | 苏州泽璟生物制药股份有限公司 | Method for preparing deuterated diphenylurea |
| CN103301066B (en) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | It is a kind of improve absorbent properties solid dispersions and its preparation |
| CN103301067B (en) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | It is a kind of improve absorbent properties solid dispersions and its preparation |
| CN103570613B (en) * | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | The polymorphic form of deuterated ω-diphenyl urea or its salt |
| CN104140418B (en) * | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2,4,5-substituted aniline) pyrimidine derivatives and application thereof |
| CN105348186B (en) * | 2015-10-15 | 2018-05-22 | 青岛海洋生物医药研究院股份有限公司 | Deuterated substituted bisarylurea compound and preparation method thereof and the application in anti-tumor drug is prepared |
-
2008
- 2008-09-19 CN CN2008102001060A patent/CN101676266B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Chetan Lathia ET AL.Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.《Cancer Chemotherapy and Pharmacology》.2006,第57卷第685-692页. * |
| D.J.Kushner ET AL.Pharmacological uses and perspectives of heavy water and deuterated compounds.《Can.J.Physiol.Pharmacol.》.1999,第77卷第79-88页. * |
| Scott Wilhelm ET AL.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.《Nature Reviews Drug Discovery》.2006,第5卷第835-844页. * |
| U. Pleiss ET AL.Syntheses of [2H3,15N],[14C]NexavarTM and its labeled metabolites.《Journal of Labelled Compounds and Radiopharmaceuticals》.2006,第49卷第603-613页. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103254126A (en) * | 2008-09-19 | 2013-08-21 | 苏州泽璟生物制药有限公司 | Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101676266A (en) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101676266B (en) | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same | |
| CN102190616B (en) | A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production | |
| JP6947644B2 (en) | Deuterated chenodeoxycholic acid derivative and drug composition containing this compound | |
| CN103965114B (en) | Deuterated phenyl amino pyrimidine compounds and comprise the pharmaceutical composition of this compound | |
| CN104109149A (en) | Deuterated diamino pyrimidine compound and pharmaceutical composition containing same | |
| JP5433087B2 (en) | Process for producing deuterated methylamine and salts thereof | |
| CN103641840B (en) | A kind of synthesis of 5-isosorbide mononitrate and purification process | |
| CN107793400A (en) | Pyridine compounds and their and its application in the medicine for preparing treatment liver diseases | |
| TW201313703A (en) | Novel crystalline forms of Azilsartan and preparation thereof | |
| CN104024262A (en) | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof | |
| CN102675018B (en) | The method for preparing deuterated diphenyl urea | |
| WO2011113203A1 (en) | Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds | |
| EP4247384A1 (en) | Fgfr inhibitors and methods of making and using the same | |
| CN102471273B (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof | |
| CN105461702A (en) | 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide crystal form | |
| CN102491918A (en) | Alanyl glutamine compound and preparation method thereof | |
| WO2010060387A1 (en) | The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof | |
| CN105669532B (en) | Nimodipine soluble derivative and its preparation method and application | |
| CN104817559A (en) | Deuterated quinazolone compound and medical compositions containing same | |
| CN102516154B (en) | Deuterium-substituted omega-diphenylurea and its derivatives, as well as pharmaceutical composition containing the same | |
| CN107474097A (en) | With antitumor action enoxolone cinnamic acid derivative（GA‑CA）Preparation method and applications | |
| CN103254126A (en) | Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds | |
| CN102803221B (en) | Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising these compounds | |
| CN105949117B (en) | Sorafenib derivative of the similar structures containing chalcone and its preparation method and application | |
| CA2925218A1 (en) | Compounds for inhibition of unregulated cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 215300 Chenfeng Road 209, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee after: Suzhou Zehuang Biopharmaceutical Co., Ltd. Address before: 215300 No. 757 Beimen Road, Yushan Town, Kunshan City, Jiangsu Province Patentee before: Suzhou Zelgen Biopharmaceuticals Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20190613 Granted publication date: 20111026 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20190816 Granted publication date: 20111026 |
|
| PD01 | Discharge of preservation of patent |